Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126547161 | 12654716 | 1 | I | 201607 | 0 | 20160815 | 20160815 | DIR | 70.00 | YR | M | N | 0.00000 | 20160812 | N | PH | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126547161 | 12654716 | 1 | PS | SENSIPAR | CINACALCET HYDROCHLORIDE | 1 | Oral | D | D | 1063822 | 20200930 | 0 | 90 | MG | QD | ||||
| 126547161 | 12654716 | 3 | C | ATORVASTATIN | ATORVASTATIN | 1 | 0 | ||||||||||||
| 126547161 | 12654716 | 5 | C | MULTIPLE VITAMIN | VITAMINS | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126547161 | 12654716 | 1 | Hyperparathyroidism |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126547161 | 12654716 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126547161 | 12654716 | Myocardial infarction |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | CASEID | RPSR COD |
|---|---|---|
| 126547161 | 12654716 | HP |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126547161 | 12654716 | 1 | 2013 | 201607 | 0 |